Nexalin Says Post Hoc ADAS-Cog Analysis Of Gen-2 SYNC Alzheimer's Trial Found 10 Of 20 Evaluable Active-Arm Patients Improved 4 Or More Points; Findings To Inform Planned U.S. Pilot Study
Share
Why It Matters
Nexalin looked back at Alzheimer's trial results and found that about half the patients on their medicine showed meaningful improvement on a thinking-and-memory test. This kind of finding helps the company plan what to try next, so it's worth watching to see if bigger studies show the same results.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.